Becton, Dickinson and Company $BDX Shares Bought by Ethic Inc.

Key Points

• Ethic Inc. increased its Becton Dickinson stake by 19.6% in the third quarter, adding 9,651 shares to hold 58,873 shares valued at about $10.5 million.
• BD reported quarterly adjusted EPS of $4.15 and revenue of $5.27 billion, beating analyst estimates; however, its fiscal 2027 revenue-growth outlook reportedly fell slightly short of expectations.
• The company raised its quarterly dividend to $1.06 per share and authorized repurchases of up to 10 million shares, approximately 3.6% of shares outstanding.

Ethic Inc. increased its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 19.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,873 shares of the medical instruments supplier's stock after buying an additional 9,651 shares during the period. Ethic Inc.'s holdings in Becton, Dickinson and Company were worth $10,538,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. TD Waterhouse Canada Inc. grew its holdings in Becton, Dickinson and Company by 17.1% in the second quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier's stock worth $14,715,000 after purchasing an additional 14,077 shares during the last quarter. Northside Capital Management LLC increased its position in shares of Becton, Dickinson and Company by 18.3% during the second quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier's stock worth $9,280,000 after purchasing an additional 9,494 shares in the last quarter. NewEdge Advisors LLC lifted its holdings in shares of Becton, Dickinson and Company by 35.0% during the 1st quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier's stock valued at $6,923,000 after purchasing an additional 11,414 shares during the last quarter. Capital Analysts LLC boosted its position in shares of Becton, Dickinson and Company by 7.5% in the 2nd quarter. Capital Analysts LLC now owns 83,601 shares of the medical instruments supplier's stock worth $12,651,000 after purchasing an additional 5,828 shares in the last quarter. Finally, Beverly Hills Private Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth $3,353,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Wall Street Analysts Forecast Growth

BDX has been the topic of several recent analyst reports. Piper Sandler upped their target price on Becton, Dickinson and Company from $175.00 to $200.00 and gave the company a "neutral" rating in a research report on Friday. UBS Group started coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a "buy" rating and a $190.00 price target for the company. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. Royal Bank Of Canada upped their price objective on shares of Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a "sector perform" rating in a report on Friday. Finally, Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $193.67.

Insider Transactions at Becton, Dickinson and Company

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company's stock, valued at $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,907 shares of company stock worth $1,269,128 over the last three months. 0.40% of the stock is currently owned by insiders.

Trending Headlines about Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported Q4 adjusted earnings of $4.15 per share and revenue of $5.27 billion, topping analyst expectations; revenue rose 5.4% year over year. BD fiscal 2026 results
• Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share and authorized repurchases of up to 10 million shares, or about 3.6% of shares outstanding. Dividend increase and share repurchase authorization
• Positive Sentiment: Citigroup raised its price target to $241 and assigned a “buy” rating; Evercore ISI also lifted its target, to $230 from $210. Citigroup analyst rating Evercore ISI price target
• Neutral Sentiment: RBC raised its target to $225 but kept a “sector perform” rating, while Piper Sandler raised its target to $200 and maintained “neutral”—below the stock’s recent trading level. RBC analyst rating Piper Sandler price target
• Negative Sentiment: The main concern is the fiscal 2027 outlook: coverage reports say revenue-growth guidance came in just below expectations, tempering the impact of the Q4 beat and prompting investor concern. Fiscal 2027 guidance coverage

Becton, Dickinson and Company Price Performance

NYSE BDX opened at $212.27 on Monday. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.87 and a quick ratio of 0.54. The stock's fifty day moving average price is $188.17 and its 200 day moving average price is $170.28. Becton, Dickinson and Company has a 1 year low of $137.35 and a 1 year high of $214.88. The company has a market cap of $58.49 billion, a price-to-earnings ratio of 51.27, a PEG ratio of 14.26 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.08. The company had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.11 billion. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The firm's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business posted $3.96 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 13.27 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be paid a $1.06 dividend. The ex-dividend date is Thursday, December 10th. This is a positive change from Becton, Dickinson and Company's previous quarterly dividend of $1.05. This represents a $4.24 annualized dividend and a dividend yield of 2.0%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 126.51%.

Becton, Dickinson and Company announced that its board has authorized a share buyback program on Thursday, November 5th that allows the company to buy back 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 3.6% of its shares through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its shares are undervalued.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies.

BD's products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Its offerings serve hospitals, clinics, laboratories, researchers and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.